10/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

MEDLAND, Peter, et al.

Serial No.:

To Be Assigned

(371 National Phase Application of PCT/GB2005/000779)

(Published as WO 2005/085244)

Filed:

Herewith

For:

3,5-disubstituted 1H-pyrrolo [2,3-B] pyridines as JNK Inhibitors

Attorney Docket No.: 102286.167 US1

PRELIMINARY AMENDMENT

EXPRESS MAIL LABEL NO.: EV 604749793 US

September 1, 2006

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Prior to the examination of the above-identified application on the merits, please amend above-identified specification and claims as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 31 of this paper.